Company Spotlight: Caristo CaRi-Plaque - 0.999 Correlation with Remote Operators

In this episode, we unpack the FDA 510(k) summary for Caristo Diagnostics' CaRi-Plaque software. We explore how this web-based device leverages remote human operators and threshold-based segmentation to achieve remarkably high correlations with expert cardiologists, and discuss the unusual demographic estimations used in its clinical validation.

Key points

• CaRi-Plaque is a web-based, Class II diagnostic reading software intended for analyzing cardiac CT data to determine coronary plaques and luminal stenoses.
• Unlike its machine-learning predicate, CaRi-Plaque uses threshold-based segmentation and relies on remote trained operators in regional data centers rather than local clinical workstations.
• Clinical validation on 117 subjects showed incredibly high Pearson Correlation Coefficients against expert ground truth, including 0.999 for Calcified Plaque Volume.
• The validation dataset was heavily skewed toward men (85 men to 32 women) and utilized estimated local census data to determine patient ethnicity for over half the subjects.
• The FDA label warns that interpolated data generated by the software may mask very small pathologies, emphasizing that the tool cannot replace a qualified practitioner's judgment.

Source: FDA 510(k) summary K242240: CaRi-Plaque (Caristo Diagnostics) - U.S. Food and Drug Administration, 2025

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Company: Caristo Diagnostics · Product: CaRi-Plaque · FDA 510(k) K242240

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/company-spotlight-caristo-cari-plaque-0-999-correlation-with-remote-op-cbe30a